259 related articles for article (PubMed ID: 29447443)
1. Inhibitor Bound Dengue NS2B-NS3pro Reveals Multiple Dynamic Binding Modes.
Gibbs AC; Steele R; Liu G; Tounge BA; Montelione GT
Biochemistry; 2018 Mar; 57(10):1591-1602. PubMed ID: 29447443
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds.
Leonel CA; Lima WG; Dos Santos M; Ferraz AC; Taranto AG; de Magalhães JC; Dos Santos LL; Ferreira JMS
Arch Virol; 2018 Mar; 163(3):575-586. PubMed ID: 29147793
[TBL] [Abstract][Full Text] [Related]
3. Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
Lai H; Teramoto T; Padmanabhan R
Methods Mol Biol; 2014; 1138():345-60. PubMed ID: 24696347
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
Erbel P; Schiering N; D'Arcy A; Renatus M; Kroemer M; Lim SP; Yin Z; Keller TH; Vasudevan SG; Hommel U
Nat Struct Mol Biol; 2006 Apr; 13(4):372-3. PubMed ID: 16532006
[TBL] [Abstract][Full Text] [Related]
5. Allosteric inhibition of the NS2B-NS3 protease from dengue virus.
Yildiz M; Ghosh S; Bell JA; Sherman W; Hardy JA
ACS Chem Biol; 2013 Dec; 8(12):2744-52. PubMed ID: 24164286
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous uncoupled expression and purification of the Dengue virus NS3 protease and NS2B co-factor domain.
Shannon AE; Chappell KJ; Stoermer MJ; Chow SY; Kok WM; Fairlie DP; Young PR
Protein Expr Purif; 2016 Mar; 119():124-9. PubMed ID: 26647367
[TBL] [Abstract][Full Text] [Related]
7. Binding of low molecular weight inhibitors promotes large conformational changes in the dengue virus NS2B-NS3 protease: fold analysis by pseudocontact shifts.
de la Cruz L; Nguyen TH; Ozawa K; Shin J; Graham B; Huber T; Otting G
J Am Chem Soc; 2011 Nov; 133(47):19205-15. PubMed ID: 22007671
[TBL] [Abstract][Full Text] [Related]
8. West Nile Virus NS2B/NS3 protease as an antiviral target.
Chappell KJ; Stoermer MJ; Fairlie DP; Young PR
Curr Med Chem; 2008; 15(27):2771-84. PubMed ID: 18991636
[TBL] [Abstract][Full Text] [Related]
9. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.
Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA
J Virol; 2017 May; 91(10):. PubMed ID: 28298600
[TBL] [Abstract][Full Text] [Related]
10. NMR analysis of a novel enzymatically active unlinked dengue NS2B-NS3 protease complex.
Kim YM; Gayen S; Kang C; Joy J; Huang Q; Chen AS; Wee JL; Ang MJ; Lim HA; Hung AW; Li R; Noble CG; Lee le T; Yip A; Wang QY; Chia CS; Hill J; Shi PY; Keller TH
J Biol Chem; 2013 May; 288(18):12891-900. PubMed ID: 23511634
[TBL] [Abstract][Full Text] [Related]
11. NMR and MD Studies Reveal That the Isolated Dengue NS3 Protease Is an Intrinsically Disordered Chymotrypsin Fold Which Absolutely Requests NS2B for Correct Folding and Functional Dynamics.
Gupta G; Lim L; Song J
PLoS One; 2015; 10(8):e0134823. PubMed ID: 26258523
[TBL] [Abstract][Full Text] [Related]
12. Binding mode of the activity-modulating C-terminal segment of NS2B to NS3 in the dengue virus NS2B-NS3 protease.
de la Cruz L; Chen WN; Graham B; Otting G
FEBS J; 2014 Mar; 281(6):1517-33. PubMed ID: 24472363
[TBL] [Abstract][Full Text] [Related]
13. Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease.
Li L; Basavannacharya C; Chan KW; Shang L; Vasudevan SG; Yin Z
Chem Biol Drug Des; 2015 Sep; 86(3):255-64. PubMed ID: 25533891
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal.
Viswanathan U; Tomlinson SM; Fonner JM; Mock SA; Watowich SJ
J Chem Inf Model; 2014 Oct; 54(10):2816-25. PubMed ID: 25263519
[TBL] [Abstract][Full Text] [Related]
15. In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.
Dwivedi VD; Tripathi IP; Mishra SK
J Vector Borne Dis; 2016; 53(2):156-61. PubMed ID: 27353586
[TBL] [Abstract][Full Text] [Related]
16. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG
Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567
[TBL] [Abstract][Full Text] [Related]
17. A Computational Approach Applied to the Study of Potential Allosteric Inhibitors Protease NS2B/NS3 from Dengue Virus.
Costa RAD; Rocha JAPD; Pinheiro AS; Costa ADSSD; Rocha ECMD; Silva RC; Gonçalves ADS; Santos CBR; Brasil DDSB
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807364
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of novel inhibitors against the NS2B-NS3 protease of dengue fever virus type 4.
Nguyen TT; Lee S; Wang HK; Chen HY; Wu YT; Lin SC; Kim DW; Kim D
Molecules; 2013 Dec; 18(12):15600-12. PubMed ID: 24352016
[TBL] [Abstract][Full Text] [Related]
19. Design and docking studies of peptide inhibitors as potential antiviral drugs for dengue virus ns2b/ns3 protease.
Velmurugan D; Mythily U; Rao K
Protein Pept Lett; 2014; 21(8):815-27. PubMed ID: 23855663
[TBL] [Abstract][Full Text] [Related]
20. The active essential CFNS3d protein complex.
Melino S; Fucito S; Campagna A; Wrubl F; Gamarnik A; Cicero DO; Paci M
FEBS J; 2006 Aug; 273(16):3650-62. PubMed ID: 16911516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
